Xenetic Biosciences, Inc.XBIONASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank87
5Y CAGR+62.4%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
+62.4%/yr
Long-term compound
Percentile
P87
Within normal range
vs 5Y Ago
11.3x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 23.94% |
| Q2 2025 | 0.17% |
| Q1 2025 | -6.95% |
| Q4 2024 | -5.37% |
| Q3 2024 | -34.01% |
| Q2 2024 | 35.35% |
| Q1 2024 | -12.30% |
| Q4 2023 | 29.13% |
| Q3 2023 | -22.06% |
| Q2 2023 | 2.18% |
| Q1 2023 | 8.00% |
| Q4 2022 | 0.22% |
| Q3 2022 | -16.66% |
| Q2 2022 | 13.11% |
| Q1 2022 | -6.30% |
| Q4 2021 | 2.45% |
| Q3 2021 | 6.11% |
| Q2 2021 | -4.28% |
| Q1 2021 | 5.68% |
| Q4 2020 | 9.50% |
| Q3 2020 | 2.12% |
| Q2 2020 | -15.13% |
| Q1 2020 | 11.19% |
| Q4 2019 | -61.05% |
| Q3 2019 | 140.52% |
| Q2 2019 | 3.17% |
| Q1 2019 | -23.24% |
| Q4 2018 | 4.24% |
| Q3 2018 | 1.17% |
| Q2 2018 | -4.95% |
| Q1 2018 | -43.59% |
| Q4 2017 | 48.02% |
| Q3 2017 | -31.81% |
| Q2 2017 | 20.55% |
| Q1 2017 | -30.53% |
| Q4 2016 | 73.04% |
| Q3 2016 | -12.70% |
| Q2 2016 | 9.51% |
| Q1 2016 | -14.57% |
| Q4 2015 | -44.22% |